Document is current
Any future updates will be listed below
-
Authors
Augustin, Matthias https://orcid.org/0000-0002-4026-8728
Barker, Jonathan https://orcid.org/0000-0002-9030-183X
Conrad, Curdin https://orcid.org/0000-0002-2547-3440
Jullien, Denis https://orcid.org/0000-0002-2995-7928
Carrascosa, Jose-Manuel https://orcid.org/0000-0003-4266-0771
Reddy, Jyotsna
Amouzadeh, Hamid
Colgan, Stephen
Zou, Henry https://orcid.org/0009-0003-1035-6772
Mrowietz, Ulrich https://orcid.org/0000-0002-9539-0712
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03774875 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life
https://doi.org/10.1007/s13555-025-01389-z
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 6 December 2024
Accepted: 14 March 2025
First Online: 3 May 2025
Declarations
:
: Matthias Augustin: Abbott/AbbVie, Almirall, Amgen Inc., Beiersdorf, Biogen Idec, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Centocor, Dermira, Eli Lilly, Fresenius, Galderma, GlaxoSmithKline, Hexal, Incyte, Janssen-Cilag, LEO Pharma, Lilly, Medac, Merck, MSD, Mylan, Novartis, Pfizer, Regeneron, Sandoz, UCB, and XenoPort—consultant, paid speaker, and/or has received research grants/honoraria. Jonathan Barker: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Samsung, Sienna, Sun Pharma, and UCB—participated in advisory boards, received consultancy fees, spoke at sponsored symposia, and/or received grant funding. Curdin Conrad: AbbVie, Actelion, Almirall, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, Eli-Lilly, MSD, Novartis, Pfizer, Samsung, and UCB—honoraria and/or research grants. Denis Jullien: AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Fresenius-Kabi, Janssen-Cilag, LEO Pharma, Lilly, Medac, MSD, Novartis, Pfizer, Sanofi, and UCB—consultant, speaker, investigator, scientific officer, steering committee member, and/or advisory board member. Jose-Manuel Carrascosa: Abbott/AbbVie, Almirall, Amgen Inc., Beiersdorf, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Fresenius, Galderma, Incyte, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, Sandoz, UCB, Sanofi-Aventis, Pfizer, Janssen—consultant, paid speaker, and/or has received research grants/honoraria. Jyotsna Reddy, Hamid Amouzadeh, Stephen Colgan, and Henry Zou: Amgen Inc.—employees and stockholders. Ulrich Mrowietz: AbbVie, Aditxt, Almirall, Amgen Inc., Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dr. Reddy’s, Eli Lilly, Foamix, Formycon, Immunic, Janssen, LEO Pharma, Medac, MetrioPharm, Novartis, Phi-Stone, Pierre Fabre, Sanofi-Aventis, and UCB Pharma, UNION therapeutics—advisor, received speakers’ honoraria, received grants, and/or participated in clinical trials.
: The study was approved by the institutional review board/ethics committee at each site before commencement and conducted in compliance with Good Clinical Practice, the International Council for Harmonisation Guideline E6, the Declaration of Helsinki, and applicable regulatory requirements (Supplementary Table ). Patients provided written informed consent before study-related procedures.
